-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2951 Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Biological, antibodies, therapy sequence, Adult, Diseases, Non-Biological, Mantle Cell Lymphoma, Therapies, Combinations, chemotherapy, B-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, transplantation, TKI
Monday, December 7, 2020, 7:00 AM-3:30 PM

Mats Jerkeman, MD, PhD1, Thorgerdur Palsdottir2*, Ingrid Glimelius, MD, PhD3*, Alexandra Albertsson-Lindblad, MD, PhD4*, Caroline Weibull5*, Fredrik Ellin, MD, PhD6*, Kristina Sonnevi, MD, PhD7*, Catharina Lewerin, MD, PhD8*, Lena Brandefors9* and Karin E. Smedby, MD, PhD10*

1Department of Oncology, Skane University Hospital, Lund, Skaane Laen, Sweden
2Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden
3Department of Immunology, Genetics and Pathology, Unit of Oncology, Uppsala University, Uppsala, Sweden
4Dept of Oncology, Institute of Clinical Sciences, Lund University, Lund, Sweden
5Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
6Department of Internal Medicine, Kalmar County Hospital, Kalmar, Sweden
7Karolinska Institutet Univeristy Hospital, Stockholm, SWE
8Sahlgrenska University Hospital, Goeteborg, Sweden
9Sunderby Sjukhus, Lulea, SWE
10Karolinska University Hospital, Stockholm, Sweden

Background Mantle cell lymphoma (MCL) is a B-cell malignancy, with increasing incidence. It is currently not considered curable. Although a proportion of patients obtain prolonged remission after first line chemoimmunotherapy, most patients will experience several lines of therapy. Hitherto, population based data of the complete care trajectories for patients with MCL have not been available, limiting our knowledge to that from single centre experiences. Here, we present the initial data from a nationwide attempt to collect all available data from all patients diagnosed with MCL.

Methods Patients with a primary diagnosis of MCL in 2006-2018 were identified in the Swedish Lymphoma Register and followed until March 6, 2020. The register contains information about clinical characteristics, prognostic factors, primary treatment, treatment response and relapse. Information on further lines of therapy, including treatment response and progression/relapse was extracted through medical chart review in all patients.

Results In total, 1411 patients were diagnosed with MCL during the period 2006-2018. Currently, complete data are available for 445 (32%). The most frequently used first line regimens were R-bendamustine (n=131, 29%) and Nordic MCL2 (n=102, 21%). 31 patients (7%) were managed with an initial watch and wait strategy. 87 patients (19%) received consolidation with an autologous stem cell transplant, and 51 (11%) patients received rituximab maintenance. After a median follow-up of 49 months (IQR 25-81), 279 patients (63%) did not experience any relapse, and the median age for patients without relapse was higher compared to the relapse group (73 vs 70 years). 166 patients (37%) experienced a first relapse or progression. The most frequently used second line regimen was R-bendamustine (n=49, 30%). 102 (21%) and 51 (11%) experienced a second or third relapse/progression, respectively. The median PFS after 1st (PFS-1), 2nd, (PFS-2), 3rd (PFS-3) and 4th (PFS-4) lines of therapy were 40, 11, 6, and 4 months. Patients with early progression, defined as a PFS-1 <24 months (POD24-1) had an inferior outcome (median OS of 23 vs. 101 months) compared to patients with a later relapse. Similarly, patients with a POD24-2 had an inferior outcome compared to patients with PFS-2 ³24 months (median OS 8.4 vs 61 months).

Conclusion In this population-based series, mainly treated with conventional chemoimmunotherapy, 63% of patients diagnosed with MCL did not experience relapse/progression after a median follow-up of 40 months – due to death before relapse or continuous remission. In addition, PFS and OS continue to drop with successive lines of therapies. Early progression, both after 1st and after 2nd line therapy is associated with markedly impaired OS –identifying patient populations in need of novel treatment strategies.

Figure 1 A. Progression-free survival (PFS) in 445 patients with mantle cell lymphoma (MCL) diagnosed in Sweden 2006-2018 according to first line regimen. B. Overall survival (OS) according to time to relapse (PFS -1 < 24 months or >24 months).

Disclosures: Jerkeman: Roche: Research Funding; Celgene: Research Funding; Abbvie: Research Funding; Janssen: Research Funding; Gilead: Research Funding. Weibull: Janssen Cilag: Research Funding. Smedby: Celgene: Consultancy; Janssen: Research Funding; Takeda: Research Funding.

*signifies non-member of ASH